
Opinion|Videos|March 11, 2025
When to Move Beyond TACE: The Expanding Role of Systemic Therapy in Intermediate-Stage HCC
Author(s)Richard S. Finn, MD, Amit Singal, MD
Panelists discuss how combining systemic therapy with locoregional treatments like transarterial chemoembolization (TACE) aims to enhance therapeutic efficacy by addressing its limitations, such as incomplete tumor necrosis and hypoxia-induced progression. Tyrosine kinase inhibitors (TKIs) like lenvatinib and immune checkpoint inhibitors (ICIs) counteract TACE-induced resistance by inhibiting angiogenesis and boosting immune response, improving overall tumor control.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- In recent years, several trials have sought to evaluate the potential synergy of combining systemic therapy with locoregional therapy. Please discuss the rationale for combining systemic therapy with locoregional treatments like TACE.
- What are the limitations of TACE monotherapy?
- How do TKIs like lenvatinib or ICIs contribute to overcoming TACE-induced tumor progression/resistance mechanisms?
- How does this combination potentially enhance treatment efficacy compared with TACE alone?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
NCCN Updates Breast Cancer Guidelines: Sacituzumab Govitecan for 1L TNBC
3
Ropeginterferon Alfa Gains NCCN Backing in Essential Thrombycythemia
4
Multiomic Real-World Data Predict Outcomes in Metastatic Breast Cancer
5


















